On Thursday, 2 September, in an interview with Jack Hodgins on 2NUR.FM’s ‘Wellbeing’ segment, Professor Bryan Williams (Cartherics Non-Executive Board Member) spoke about COVID-19, viruses and how vaccines control them, and the importance of medical research.
“I would encourage Australians to convince their politicians that they need to increase the research budget in Australia, […]
By Leigh Dayton
27 August 2021
Cartherics CEO Alan Trounson congratulates Natalia Benetti for her important research in developmental cell biology: “It’s great work and very well presented”.
The company also applauds the Australian Regenerative Medicine Institute for successfully organising the 13th Victorian State Conference of the […]
By Leigh Dayton
9 August 2021
Cartherics is pleased to announce that CEO Alan Trounson has been congratulated by the National Library of Australia for his recognition on this year’s Queen’s Birthday Honours List.
In recognition of his “distinguished service to medical science, and to in vitro fertilisation and stem cell technologies” Trounson was appointed an […]
By Leigh Dayton
22 July 2021
Cartherics is delighted to announce that it is a sponsor of the Australia and New Zealand Society of Cell and Developmental Biology’s Victorian State Conference. The highly regarded one-day event is booked for 26 August at the University of Melbourne.
Cartherics CEO Alan Trounson welcomes the opportunity to support the meeting.
“It is […]
Cartherics Pty Ltd and the Australian Regenerative Medicine Institute (ARMI), including commercialisation initiative CCRM Australia, announced agreements for closer cooperation and collaboration today.
“Cartherics affiliation with ARMI is an important step in our development and will embed industry and academic excellence in regenerative medicine and translation to clinical medicine in cancer,” said Prof Alan Trounson, Cartherics […]
Melbourne, Australia and Seoul, South Korea
28 June 2021
Cartherics Pty Ltd (“Cartherics”) and ToolGen, Inc. (“ToolGen”) announced today that they have entered into a commercial licence agreement.
Under the agreement, Cartherics obtains […]
By Heather Hawkins
24 May 2021
Even today – and it’s been 14 years since diagnosis – they still evoke a very raw and deeply emotional response. It was the first time I’d faced the undeniable fact […]
Four Australian women are diagnosed with ovarian cancer a day and three will eventually die from the disease. It’s usually diagnosed late, because few women show symptoms until they have advanced cancer.
As a junior doctor in London in the mid-1980s, Ian Jacobs saw women undergo chemo and […]
The first in a provocative series on the complexities of advanced therapeutic approaches to cancer
By Jeff Brockman and Joel Sandler of Cello Health BioConsulting
“In 1890, the Russian playwright and physician Anton Chekov (pictured above) wrote a letter in which he alluded to a centuries-old observation that infections seemed to slow the growth of […]
Melbourne, Australia, 04 March 2021.
Cartherics Pty Ltd announced today the grant of a European patent entitled “Genetically modified cells and uses thereof”. The patent covers aspects of Cartherics’ chimeric antigen receptor (CAR) technology, particularly in relation to its CAR directed against the tumour-associated antigen, TAG-72.
This patent is […]
Cartherics’ mission is the development of novel, “off-the-shelf” (allogeneic) immune cell therapy products for the treatment of cancer.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
